论文部分内容阅读
目的通过建立裸鼠C6胶质瘤动物模型,观察环氧化酶2(COX-2)选择性抑制剂塞来昔布(celecoxib)对恶性胶质瘤放疗的增敏作用并对其作用机理进行初步探讨。方法Balb/c裸鼠15只,体外培养大鼠c6胶质瘤细胞,接种于裸鼠右肩皮下建立肿瘤模型。肿瘤形成后随机分成3组:对照组、放疗组、塞来布昔+放疗组。用灌肠法给予塞来昔布16mg/kg/d,4周时对比两组肿瘤瘤重;采用免疫组化方法,分析共济失调-毛细血管扩张症突变蛋白(ATM)和表皮生长因子受体(EGFR)表达变化。结果周时塞来布昔+放疗组与放疗组比较差异有统计学意义(P<0.05)。结论塞来昔布可能通过提高ATM和EGFR的表达增强胶质瘤细胞的放疗敏感性;COX-2选择性抑制剂塞来昔布对胶质瘤的治疗可能具有临床应用价值。
OBJECTIVE: To establish an animal model of C6 glioma in nude mice and observe the sensitizing effect of celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, on the radiotherapy of malignant glioma and to investigate its mechanism of action Preliminary discussion. Methods Fifteen Balb / c nude mice were cultured in vitro with c6 glioma cells and inoculated into the right shoulder of nude mice to establish a tumor model. The tumors were randomly divided into 3 groups: control group, radiotherapy group, celecuboxide + radiotherapy group. Celecoxib 16 mg / kg / d was administrated by enema method, and the tumor weight was compared at 4 weeks. Immunohistochemistry was used to analyze the relationship between ataxia-telangiectasia mutant protein (ATM) and epidermal growth factor receptor (EGFR) expression changes. Results Compared with radiotherapy group, the difference was statistically significant (P <0.05). Conclusion Celecoxib may enhance the radiosensitivity of glioma cells by increasing the expression of ATM and EGFR. Celecoxib, a selective COX-2 inhibitor, may have clinical value in the treatment of gliomas.